Pipeline products

We develop routes industrial synthesis

At MOEHS we constantly strive to develop synthetic industrial routesfor new Active Ingredients under criteria of commercial, industrial and intellectual property viability.

Our commercial department is at your disposal to update any details about the status
of our new developments.

At MOEHS we constantly strive to develop industrial synthesis routes for new Active Ingredients under criteria of commercial viability, industrial and intellectual property. Our sales department is at your disposal to update any details about the status of our new developments.

Products in stage of production

Product NameCAS N°Therapeutic CategoryAdditional InformationDMF / TP
EDOXABAN (**)1229194-11-9Oral anticoagulant Validation batchesDMF
ELAGOLIX (**)832720-36-2Uterine Fibroids, Endometriosis painValidation  batchesTP
EMPAGLIFLOZIN (**)864070-44-0AntidiabeticValidation batchesDMF
LASMIDITAN (**)439239-90-4Acute AntimigraineLaboratory batchesTP
LEMBOREXANT (**)1369764-02-2Insomnia treatmentLaboratory batchesTP
LEVOBUPIVACAINE HCL27262-48-2
Local Anesthetic-Antiarrhythmic Validation batchesTP
MAVACAMTEN (**)1642288-47-8CardiovascularLaboratory batches
OBETICHOLIC ACID (**)459789-99-2Liver and gastrointestinal disordersLaboratory batchesTP
PATIROMER CALCIUM SORBITEX (**)1260645-52-4HyperkalemiaLaboratory batchesTP
RELUGOLIX (**)737789-87-6Advanced prostate cancerLaboratory batchesTP
REMIMAZOLAM (**)308242-62-8
SedativeLaboratory batches TP
RIMEGEPANT (**)1289023-67-1AntimigraineLaboratory batchesTP
RIVAROXABAN (**)366789-02-8
Antibleeding agent Validation batchesDMF
SITAGLIPTIN PHOSPHATE (**)654671-77-9
AntidiabeticValidation batches DMF
TIRBANIBULIN (**)897016-82-9
Actinic KeratosisLaboratory batches TP
VERICIGUAT (**)1350653-20-1
AntihypertensiveLaboratory  batches TP
VILDAGLIPTIN (**)274901-16-5
AntidiabeticValidation batches DMF

New Products under testing

Product NameCAS N°Brand NameTherapeutic CategoryGalenic Form
MAVACAMTEN (**)1642288-47-8Cardiovascularcapsules
VERICIGUAT (**)1350653-20-1Antihypertensivetablets

(**) Moehs is working on this compound with experimental aims, exclusively directed to obtain market authorizations of our customers’ generic medicines. We don’t intend to make any activity against any valid patent protection, as well as we will not take charge of third party actions made with the provided compound and without our knowledge against this protection.